On Friday, JPMorgan reinstated coverage on Teleperformance (TEP:FP) (OTC: TLPFY), assigning the stock an Underweight rating along with a price target of EUR88.00.
The firm's stance comes amid a division in market sentiment regarding the impact of GenAI on the customer experience (CX) industry. Some investors believe GenAI signals the end of the traditional CX business model, while others view it as a new tool for CX companies to incorporate without justifying a de-rating of their stocks.
Teleperformance, a company specializing in outsourced omnichannel customer experience management, is expected to meet its current guidance, bolstered by the synergies from its Majorel acquisition.
However, JPMorgan projects that Teleperformance may face challenges meeting the consensus expectations for earnings growth in the medium term.
The analysis suggests that the company's earnings growth algorithm is undergoing a transformation, and the industry is still in the early stages of adjusting to this change.
The report indicates that while Teleperformance is poised to leverage artificial intelligence in delivering combined solutions, the broader outlook remains cautious. The firm anticipates that persistent deflationary pressures from offshoring, coupled with an acceleration in automation-related deflation, will contribute to margin headwinds for Teleperformance and its peers in the sector.
Despite these challenges, the firm acknowledges that the mix shift towards automation and offshoring could potentially support margins in the medium term. Still, the near-term outlook is tempered by the expectation of margin pressures as the industry adapts to the evolving landscape influenced by technological advancements and shifting market dynamics.
In other recent news, Teleperformance has been the subject of notable attention from investment firms Berenberg and Morgan Stanley. Berenberg maintained a Buy rating on Teleperformance, following a survey of 150 companies that outsource their customer experience (CX) operations.
The survey results indicated positive trends for Teleperformance's valuation, leading Berenberg to reaffirm its confidence in the company's growth trajectory.
On the other hand, Morgan Stanley upgraded Teleperformance from Equalweight to Overweight. This upgrade was prompted by a diminished impact of AI-related news on the company's performance and confidence in Teleperformance's 2024 guidance, which the firm described as attainable.
Furthermore, Teleperformance is expected to release midterm guidance by early 2025, providing clarity on the company's future prospects. Morgan Stanley also hinted at potential additional cash returns to shareholders before year-end.
Finally, Teleperformance's marketing efforts across Europe have stimulated increased investor interest. These are some of the recent developments in Teleperformance's ongoing journey.
InvestingPro Insights
While JPMorgan's outlook on Teleperformance (OTC: TLPFY) is cautious, recent data from InvestingPro offers a more nuanced perspective. The company's P/E ratio of 8.89 suggests it's trading at a relatively low earnings multiple, which could be attractive to value investors despite the challenges outlined in the JPMorgan report. Additionally, Teleperformance's revenue growth of 15.83% over the last twelve months indicates the company is still expanding its business, potentially offsetting some concerns about future earnings growth.
InvestingPro Tips highlight that Teleperformance has maintained dividend payments for 33 consecutive years, demonstrating a commitment to shareholder returns even as it navigates industry changes. This consistency could provide some stability for investors amid the uncertainty surrounding the impact of GenAI on the CX industry.
It's worth noting that while JPMorgan has assigned an Underweight rating, the InvestingPro Fair Value for Teleperformance stands at $78.89, significantly higher than its previous closing price of $51.30. This discrepancy suggests there may be upside potential not fully recognized in the JPMorgan analysis.
For investors seeking a more comprehensive view, InvestingPro offers 7 additional tips that could provide further insights into Teleperformance's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.